506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
A Phase II Study of 506U78 in Patients With Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphomas (LBL)
4 other identifiers
interventional
35
1 country
91
Brief Summary
Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2 leukemia
91 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 1998
CompletedFirst Submitted
Initial submission to the registry
November 1, 1999
CompletedFirst Posted
Study publicly available on registry
February 16, 2004
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2007
CompletedFebruary 5, 2013
April 1, 2007
8.6 years
November 1, 1999
February 4, 2013
Conditions
Keywords
Study Arms (1)
Arm I
EXPERIMENTALPatients receive 506U78 IV over 2 hours on days 1, 3, and 5. If residual leukemia/lymphoma is present on day 22, then patients receive a second course of 506U78. If day 22 marrow is hypocellular, then a repeat bone marrow biopsy should be obtained on day 29 to assess response. For day 22 or 29 marrow that is in complete response, patients receive 506U78 for two more courses on days 1, 3, and 5, administered every 21 days. Patients are followed every 3 month for 1 year, then every 6 months for a maximum of 10 years.
Interventions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
- National Cancer Institute (NCI)lead
- SWOG Cancer Research Networkcollaborator
Study Sites (91)
MBCCOP - Gulf Coast
Mobile, Alabama, 36688, United States
CCOP - Greater Phoenix
Phoenix, Arizona, 85006-2726, United States
Veterans Affairs Medical Center - Phoenix (Hayden)
Phoenix, Arizona, 85012, United States
Veterans Affairs Medical Center - Tucson
Tucson, Arizona, 85723, United States
Arizona Cancer Center
Tucson, Arizona, 85724, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
Veterans Affairs Medical Center - Little Rock (McClellan)
Little Rock, Arkansas, 72205, United States
Cancer Center and Beckman Research Institute, City of Hope
Duarte, California, 91010-3000, United States
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822, United States
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804, United States
Veterans Affairs Medical Center - West Los Angeles
Los Angeles, California, 90073, United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781, United States
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553, United States
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305, United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
University of California Davis Medical Center
Sacramento, California, 95817, United States
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403, United States
Stanford University
Stanford, California, 94305, United States
David Grant Medical Center
Travis Air Force Base, California, 94535, United States
University of Colorado Cancer Center
Denver, Colorado, 80010, United States
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220, United States
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701, United States
Dwight David Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650, United States
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813, United States
MBCCOP - University of Illinois at Chicago
Chicago, Illinois, 60612-7323, United States
CCOP - Central Illinois
Decatur, Illinois, 62526, United States
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, 60141, United States
Loyola University Medical Center
Maywood, Illinois, 60153, United States
University of Kansas Medical Center
Kansas City, Kansas, 66160-7357, United States
CCOP - Wichita
Wichita, Kansas, 67214-3882, United States
Veterans Affairs Medical Center - Wichita
Wichita, Kansas, 67218, United States
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40511-1093, United States
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084, United States
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112, United States
Tulane University School of Medicine
New Orleans, Louisiana, 70112, United States
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, 71130-3932, United States
Veterans Affairs Medical Center - Shreveport
Shreveport, Louisiana, 71130, United States
Boston Medical Center
Boston, Massachusetts, 02118, United States
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130, United States
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105, United States
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752, United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379, United States
Veterans Affairs Medical Center - Detroit
Detroit, Michigan, 48201-1932, United States
Henry Ford Hospital
Detroit, Michigan, 48202, United States
CCOP - Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, 49503, United States
Providence Hospital - Southfield
Southfield, Michigan, 48075-9975, United States
CCOP - Duluth
Duluth, Minnesota, 55805, United States
Veterans Affairs Medical Center - Biloxi
Biloxi, Mississippi, 39531-2410, United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505, United States
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216, United States
Keesler Medical Center - Keesler AFB
Keesler Air Force Base, Mississippi, 39534-2576, United States
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, 64128, United States
CCOP - Kansas City
Kansas City, Missouri, 64131, United States
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807, United States
St. Louis University Health Sciences Center
St Louis, Missouri, 63110-0250, United States
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141, United States
CCOP - Montana Cancer Consortium
Billings, Montana, 59101, United States
Veterans Affairs Medical Center - Albuquerque
Albuquerque, New Mexico, 87108-5138, United States
MBCCOP - University of New Mexico HSC
Albuquerque, New Mexico, 87131, United States
Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
CCOP - Southeast Cancer Control Consortium
Winston-Salem, North Carolina, 27104-4241, United States
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45219, United States
Veterans Affairs Medical Center - Cincinnati
Cincinnati, Ohio, 45220-2288, United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195, United States
CCOP - Columbus
Columbus, Ohio, 43206, United States
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428, United States
CCOP - Dayton
Kettering, Ohio, 45429, United States
CCOP - Toledo Community Hospital Oncology Program
Toledo, Ohio, 43623-3456, United States
Veterans Affairs Medical Center - Oklahoma City
Oklahoma City, Oklahoma, 73104, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73190, United States
Oregon Cancer Center
Portland, Oregon, 97201-3098, United States
Veterans Affairs Medical Center - Portland
Portland, Oregon, 97207, United States
CCOP - Columbia River Program
Portland, Oregon, 97213, United States
CCOP - Greenville
Greenville, South Carolina, 29615, United States
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303, United States
Simmons Cancer Center - Dallas
Dallas, Texas, 75235-9154, United States
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234, United States
University of Texas Medical Branch
Galveston, Texas, 77555-0209, United States
Texas Tech University Health Science Center
Lubbock, Texas, 79423, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78284-7811, United States
Veterans Affairs Medical Center - San Antonio (Murphy)
San Antonio, Texas, 78284, United States
Veterans Affairs Medical Center - Temple
Temple, Texas, 76504, United States
CCOP - Scott and White Hospital
Temple, Texas, 76508, United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
Veterans Affairs Medical Center - Salt Lake City
Salt Lake City, Utah, 84148, United States
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101, United States
Swedish Cancer Institute
Seattle, Washington, 98104, United States
Veterans Affairs Medical Center - Seattle
Seattle, Washington, 98108, United States
CCOP - Northwest
Tacoma, Washington, 98405-0986, United States
Madigan Army Medical Center
Tacoma, Washington, 98431-5000, United States
Related Publications (2)
DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136-42. doi: 10.1182/blood-2006-11-056754. Epub 2007 Mar 7.
PMID: 17344466RESULTDe Angelo DJ, Yu D, Dodge RK, et al.: A phase II study of 2-amino-9-b-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-Lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): CALGB study 19801. [Abstract] Blood 100 (11 Pt 1): A-743, 2002.
RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute
- STUDY CHAIR
Steven E. Coutre, MD
Stanford University
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 1, 1999
First Posted
February 16, 2004
Study Start
August 1, 1998
Primary Completion
March 1, 2007
Last Updated
February 5, 2013
Record last verified: 2007-04